Results 41 to 50 of about 54,087 (251)

Tranexamic acid to reduce head injury death in people with traumatic brain injury: the CRASH-3 international RCT

Health Technology Assessment, 2021
Background: Tranexamic acid safely reduces mortality in traumatic extracranial bleeding. Intracranial bleeding is common after traumatic brain injury and can cause brain herniation and death.
Ian Roberts, Haleema Shakur-Still, Amy Aeron-Thomas, Danielle Beaumont, Antonio Belli, Amy Brenner, Madeleine Cargill, Rizwana Chaudhri, Nicolas Douglas, Lauren Frimley, Catherine Gilliam, Amber Geer, Zahra Jamal, Rashid Jooma, Raoul Mansukhani, Alec Miners, Jason Pott, Danielle Prowse, Temitayo Shokunbi, Jack Williams   +19 more
doaj   +1 more source

Plasmin Inhibitor in Health and Diabetes: Role of the Protein as a Therapeutic Target

TH Open, 2022
The vascular obstructive thrombus is composed of a mesh of fibrin fibers with blood cells trapped in these networks. Enhanced fibrin clot formation and/or suppression of fibrinolysis are associated with an increased risk of vascular occlusive events ...
Basmah Alsayejh, Noppadol Kietsiriroje, Mansour Almutairi, Katie Simmons, Nikoletta Pechlivani, Sreenivasan Ponnambalam, Ramzi A. Ajjan   +6 more
doaj   +1 more source

Management of dental extraction in patients with Haemophilia A and B: a report of 58 extractions [PDF]

, 2014
Objectives: Patients with inherited bleeding disorders are at high risk of bleeding following oral surgery and present challenges to the oral surgeons. Aim of this study was to report our experience in dental extraction in patients exhibiting Haemophilia
Peisker, Andre, Raschke, Gregor-Franziskus, Schultze Mosgau, Stefan   +2 more
core   +1 more source

Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1 [PDF]

, 2020
Current antifibrinolytic agents reduce blood loss by inhibiting plasmin active sites (e.g., aprotinin) or by preventing plasminogen/tissue plasminogen activator (tPA) binding to fibrin clots (e.g., ε-aminocaproic acid and tranexamic acid); however, they ...
Arbing, Mark A, Bajaj, S Paul, Buchholz, Wallace G, Fabian, Frank M, Ismail, Ayman E.A., Kumar, Yogesh, Vadivel, Kanagasabai, Velander, William H, Zaiss, Anne K   +8 more
core   +2 more sources

Minimal Dose of Tranexamic Acid Is Effective in Reducing Blood Loss in Complex Spine Surgeries: A Randomized Double-Blind Placebo Controlled Study [PDF]

Asian Spine Journal, 2018
Study Design A randomized double-blind placebo controlled study. Purpose In the present study, we aimed to assess the efficacy of tranexamic acid (TXA) in reducing blood loss after laminectomy and posterolateral fusion of the spine.
Moslem Shakeri, Firooz Salehpour, Ghaffar Shokouhi, Kamkar Aeinfar, Javad Aghazadeh, Farhad Mirzaei, Seyed Ahmad Naseri Alavi   +6 more
doaj   +1 more source

Fast selection of nonlinear mixed effect models using penalized likelihood [PDF]

arXiv, 2021
Nonlinear Mixed effects models are hidden variables models that are widely used in many fields such as pharmacometrics. In such models, the distribution characteristics of hidden variables can be specified by including several parameters such as covariates or correlations which must be selected.
arxiv  

Coagulation and Bleeding Management in Pediatric Extracorporeal Membrane Oxygenation: Clinical Scenarios and Review

Frontiers in Medicine, 2019
Extracorporeal membrane oxygenation (ECMO) is a life-saving procedure that requires careful coagulation management. Indications for ECMO continue to expand, leading to more complicated patients treated by ECMO teams.
Lisa A. Hensch, Lisa A. Hensch, Shiu-Ki Rocky Hui, Shiu-Ki Rocky Hui, Jun Teruya, Jun Teruya   +5 more
doaj   +1 more source

Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk [PDF]

, 2017
An enhanced thrombotic environment and premature atherosclerosis are key factors for the increased cardiovascular risk in diabetes. The occlusive vascular thrombus, formed secondary to interactions between platelets and coagulation proteins, is composed ...
A Agren, A Ceriello, A Hamsten, A Hamsten, A Lados-Krupa, A Liang, A Lutjens, A Rouch, A Rupin, A Sahebkar, A Tripodi, A Undas, A Undas, A Undas, AH Guimaraes, AH Henschen-Edman, AH Straten van, AS Wolberg, AS Wolberg, B Blomback, B Craen Van De, B Lipinski, B Rocca, B Wiman, B Zinman, BH Shieh, C Longstaff, CH Lundgren, CH Nair, CL Nikolajsen, CS Fox, D Capodanno, D Hill, D Leenaerts, D Ricklin, DA Gabriel, DA Lawrence, DA Lawrence, Darren Tomlinson, DJ Schneider, DL Crandall, DV Sakharov, E Angelantonio Di, E Chow, E Ernst, E Pretorius, E Pretorius, E Shacter, E Vercauteren, EG Levin, EJ Dunn, EJ Dunn, EL Hethershaw, EM Sherif, F Denorme, F Rollini, G Boden, G Gajos, G Jorneskog, GJ Brouwers, GK Hansson, GL Booth, GL Reed 3rd, GL Reed 3rd, H Elokdah, H Ritchie, HC Gerstein, HH Versteeg, HJ Beijers, HK Kim, I Juhan-Vague, I Shimomura, J Bester, J Danesh, J Montaner, J Svensson, J Weisel, JA Dormandy, JC Chapin, JD Mills, JG Dillinger, JH Foley, JL Ferreiro, JL Mega, JM Howes, JP Collet, JP Collet, JW Weisel, K Bangert, K Buelens, K Distelmaier, K Fatah, K Hess, K Hess, K Hess, K Leander, K Leander, Katherine Kearney, KE Brummel, Kerrie Smith, KN Lee, KN Lee, KN Lee, KN Lee, KN Lee, KR Machlus, L Badimon, L Ryden, L Wallentin, LM Belalcazar, M Konieczynska, M Pieters, M Pieters, M Pieters, M Rigla, M Udvardy, MA Bailey, MB Kahn, MC Alessi, ME Carr Jr, ME Meltzer, ME Meltzer, ME Meltzer, ME Stegenga, MG Marini, MR Hammer, MS Ardawi, N Gogitidze Joy, N Zheng, NH Tilburg van, NV Gorlatova, O Sigurdardottir, OJ Phung, P Chudy, P Clemmensen, P Katz, P Kohli, P Soma, P Soma, R Ajjan, R Favier, R King, RA Ajjan, RA Ajjan, RA Al-Horani, Ramzi Ajjan, RM Cubbon, RM Missov, RP Rother, RR Holman, S James, S Kimura, S Kimura, S Neergaard-Petersen, S Schulman, S Tehrani, S Tehrani, S Yener, SD Wiviott, SD Wiviott, SH Alzahrani, SH Alzahrani, SJ Cleland, SK Kunutsor, SL Carpenter, SP Marso, SR Fraser, ST Lord, T Koyama, T Kumada, T Lisman, T Plug, T Sasaki, T Tamaki, T Wyseure, T Wyseure, TC Holten van, TW Meade, U Amara, V Baeriswyl, VR Richardson, WB Kannel, X Zhou, X Zhou, Y Hori, Y Sakata, Y Sakata, Y Sakata, Y Sumi, Y Yano, YM Fortenberry, Z Valnickova   +191 more
core   +2 more sources

Safety and Efficacy of Hospital Utilization of Tranexamic Acid in Civilian Adult Trauma Resuscitation [PDF]

, 2020
Introduction: Patients with trauma-induced coagulopathies may benefit from the use of antifibrinolytic agents, such as tranexamic acid (TXA). This study evaluated the safety and efficacy of TXA in civilian adults hospitalized with traumatic hemorrhagic ...
Borger, Rodney, Chandwani, Deepak, Comunale, Mark E., Dong, Fanglong, Inaba, Kenji, Lowe, Andrew, Neeki, Michael, Powell, Joe, Quispe, Juan, Rabiei, Massoud, Salameh, Joseph, Toy, Jake, Vara, Richard, Wong, David   +13 more
core  

Topical use of tranexamic acid in coronary artery bypass operations: A double-blind, prospective, randomized, placebo-controlled study [PDF]

, 2000
Objectives: We sought to investigate the effect of topical application of tranexamic acid into the pericardial cavity in reducing postoperative blood loss in coronary artery surgery.
Alessandrini, Francesco, Cavaliere, Franco, De Bonis, Michele, Lapenna, Elisabetta, Moscato, Umberto, Possati, Gian Federico, Santarelli, Filippo, Schiavello, Rocco   +7 more
core   +1 more source